Simon Moroney

Last updated on 2013-11-30T00:43+0300.

About this image

sign

Quotes... Extracted quotes from

Simon Moroney said : "MorphoSys continued to make excellent progress on multiple fronts in the second quarter of 2019," External link

finanznachrichten-en Wednesday, August 7, 2019 12:19:00 AM EAT

Simon Moroney said : "This deal gives us access to a unique set of drug candidates with exciting potential in cancer" External link

finanznachrichten-en Monday, July 8, 2019 11:55:00 PM EAT

Simon Moroney commented : "On behalf of the Management Board and the Company, I would like to thank our shareholders for their continued support and trust," External link

finanznachrichten-en Thursday, May 23, 2019 1:04:00 AM EAT

Simon Moroney commented : "On behalf of the Management Board and the Company, I would like to thank our shareholders for their continued support and trust," External link

4-traders Wednesday, May 22, 2019 11:40:00 PM EAT

Simon Moroney said : "The year 2018 was an outstanding one for MorphoSys. Our achievements in R&D, corporate development and in strengthening the company's finances combine to take us significantly closer to our objective of making MorphoSys a fully integrated biopharmaceutical company," External link

finanznachrichten-en Thursday, March 14, 2019 3:25:00 AM EAT

Simon Moroney commented : "Our proprietary development program MOR208 for aggressive lymphoma was recently awarded Breakthrough Therapy designation by the FDA based on encouraging clinical data from our L-MIND trial in relapsed/refractory DLBCL. We are now focused on working closely with the regulatory authorities to bring MOR208 to market as fast as possible. The launch in the United States of Janssen's Tremfya TM (guselkumab) for moderate to severe plaque psoriasis was a major highlight of this quarter. Approval in a second major territory may be imminent based on the positive recommendation for guselkumab by the European regulatory authority. We expect guselkumab to become an important pillar of our revenue in the years ahead" External link

finanznachrichten-en Tuesday, November 7, 2017 11:26:00 AM EAT

Simon Moroney said : "We have seen significant progress, both with our own and our partners' drug candidates in the second quarter of 2017. Our progress was particularly evidenced by the start of a phase 3 trial with our blood cancer compound MOR208. This is the first pivotal study with a compound from our own development portfolio and a major milestone for MorphoSys ," External link

4-traders Thursday, August 3, 2017 8:16:00 AM EAT

Simon Moroney said : "We are very pleased to announce the successful completion of our placement which we believe reflects both the significant progress made at MorphoSys over the past years and the great confidence of investors in the potential of our pipeline," External link

finanznachrichten-en Wednesday, November 16, 2016 3:09:00 AM EAT

Simon Moroney commented : "The development of our most advanced proprietary programs MOR208 and MOR202 is progressing well. In the ongoing MOR202 trial, we have started the highest dosage cohorts of MOR202 alone and in combination with lenalidomide and pomalidomide, and we are very encouraged as we see response rates deepening over time," External link

4-traders Monday, August 1, 2016 8:20:00 AM EAT

Simon Moroney said ( about Anderson Cancer ) : "We are excited to join forces with MD Anderson, one of the world's most respected cancer research and care institutions, to work on bringing cancer treatment to a new level," External link

4-traders Tuesday, May 24, 2016 8:43:00 AM EAT



Key Titles and Phrases Count Lang Last Seen
chief executive officer83.64%EN08/10/201710/08/2017
secretary7.27%EN01/24/201724/01/2017
former munster council secretary7.27%EN11/28/201328/11/2013
chef1.82%DE03/01/200601/03/2006
Names Lang Count
Simon MoroneyEN65.52%
Simon MoroneyDE34.48%


 
Show/hide duplicate news articles.
<<10<12345678910>>>10
 
Show/hide duplicate news articles.
<<10<12345678910>>>10

Tools

Load latest edition

Friday, June 5, 2020

9:49:00 AM EAT

Languages Collapse menu...Expand menu...

Select your languages

af
am
ar
de
en
es
fr
ha
pt
rw
sw
all
Show additional languagesHide additional languages

Interface:

Legend Collapse menu...Expand menu...


Quotes... Explore Relations


EMM Visual Explorer


AfricaBrief

Simon Moroney

Last updated on 2013-11-30T00:43+0300.

About this image

sign

Quotes... Extracted quotes from

Simon Moroney said : "MorphoSys continued to make excellent progress on multiple fronts in the second quarter of 2019," External link

finanznachrichten-en Wednesday, August 7, 2019 12:19:00 AM EAT

Simon Moroney said : "This deal gives us access to a unique set of drug candidates with exciting potential in cancer" External link

finanznachrichten-en Monday, July 8, 2019 11:55:00 PM EAT

Simon Moroney commented : "On behalf of the Management Board and the Company, I would like to thank our shareholders for their continued support and trust," External link

finanznachrichten-en Thursday, May 23, 2019 1:04:00 AM EAT

Simon Moroney commented : "On behalf of the Management Board and the Company, I would like to thank our shareholders for their continued support and trust," External link

4-traders Wednesday, May 22, 2019 11:40:00 PM EAT

Simon Moroney said : "The year 2018 was an outstanding one for MorphoSys. Our achievements in R&D, corporate development and in strengthening the company's finances combine to take us significantly closer to our objective of making MorphoSys a fully integrated biopharmaceutical company," External link

finanznachrichten-en Thursday, March 14, 2019 3:25:00 AM EAT

Simon Moroney commented : "Our proprietary development program MOR208 for aggressive lymphoma was recently awarded Breakthrough Therapy designation by the FDA based on encouraging clinical data from our L-MIND trial in relapsed/refractory DLBCL. We are now focused on working closely with the regulatory authorities to bring MOR208 to market as fast as possible. The launch in the United States of Janssen's Tremfya TM (guselkumab) for moderate to severe plaque psoriasis was a major highlight of this quarter. Approval in a second major territory may be imminent based on the positive recommendation for guselkumab by the European regulatory authority. We expect guselkumab to become an important pillar of our revenue in the years ahead" External link

finanznachrichten-en Tuesday, November 7, 2017 11:26:00 AM EAT

Simon Moroney said : "We have seen significant progress, both with our own and our partners' drug candidates in the second quarter of 2017. Our progress was particularly evidenced by the start of a phase 3 trial with our blood cancer compound MOR208. This is the first pivotal study with a compound from our own development portfolio and a major milestone for MorphoSys ," External link

4-traders Thursday, August 3, 2017 8:16:00 AM EAT

Simon Moroney said : "We are very pleased to announce the successful completion of our placement which we believe reflects both the significant progress made at MorphoSys over the past years and the great confidence of investors in the potential of our pipeline," External link

finanznachrichten-en Wednesday, November 16, 2016 3:09:00 AM EAT

Simon Moroney commented : "The development of our most advanced proprietary programs MOR208 and MOR202 is progressing well. In the ongoing MOR202 trial, we have started the highest dosage cohorts of MOR202 alone and in combination with lenalidomide and pomalidomide, and we are very encouraged as we see response rates deepening over time," External link

4-traders Monday, August 1, 2016 8:20:00 AM EAT

Simon Moroney said ( about Anderson Cancer ) : "We are excited to join forces with MD Anderson, one of the world's most respected cancer research and care institutions, to work on bringing cancer treatment to a new level," External link

4-traders Tuesday, May 24, 2016 8:43:00 AM EAT



Key Titles and Phrases Count Lang Last Seen
chief executive officer83.64%EN08/10/201710/08/2017
secretary7.27%EN01/24/201724/01/2017
former munster council secretary7.27%EN11/28/201328/11/2013
chef1.82%DE03/01/200601/03/2006
Names Lang Count
Simon MoroneyEN65.52%
Simon MoroneyDE34.48%


<<10<12345678910>>>10
<<10<12345678910>>>10

Tools

Load latest edition

Friday, June 5, 2020

9:49:00 AM EAT


Quotes... Explore Relations


EMM Visual Explorer